Can Entresto and Eplerenone Cause AKI?
Yes, both Entresto (sacubitril/valsartan) and eplerenone can cause acute kidney injury (AKI), and this risk requires mandatory serial monitoring of renal function during treatment with either medication.
Entresto (Sacubitril/Valsartan) and AKI Risk
FDA-Labeled Renal Safety Concerns
Entresto carries an explicit FDA warning about kidney problems, stating that "kidney problems are common during treatment with ENTRESTO and can be serious and can lead to kidney failure" 1. The drug label mandates that doctors check kidney function during treatment and may need to lower the dose, temporarily stop, or permanently discontinue treatment if renal function deteriorates 1.
Mechanism of Renal Injury
As a consequence of inhibiting the renin-angiotensin-aldosterone system (RAAS), decreases in renal function should be anticipated in susceptible individuals 1. In patients whose renal function depends on RAAS activity (particularly those with severe heart failure), treatment has been associated with oliguria, progressive azotemia, and rarely acute renal failure and death 1.
Real-World Evidence
Recent pharmacovigilance data from the FAERS database demonstrates a significant association between sacubitril/valsartan and acute renal failure, with positive signals detected across multiple statistical algorithms (ROR = 2.37, PRR = 2.34) 2. The analysis revealed that AKI typically occurs within 30 days of initiation, with hospitalization rates of 14-30% for acute renal failure outcomes 2.
In clinical practice studies, AKI was the most common adverse effect, occurring in 14% of hospitalized patients started on sacubitril/valsartan 3. Another study found that 7% of patients required discontinuation specifically due to AKI 4.
Comparative Safety
Importantly, when compared to valsartan alone, sacubitril/valsartan carries a higher renal safety risk based on pharmacovigilance signal analysis 5. However, in older Medicare beneficiaries with heart failure, sacubitril/valsartan was not associated with higher rates of AKI hospitalization compared to traditional renin-angiotensin system inhibitors (HR 0.91,95% CI: 0.72-1.16) 6.
Eplerenone and AKI Risk
Guideline-Based Evidence
The ESC Guidelines explicitly state that eplerenone can cause worsening renal function, which was uncommon in randomized trials but occurs more frequently in ordinary clinical practice, especially in the elderly 7. The guidelines mandate serial monitoring of serum electrolytes and renal function 7.
Specific Monitoring Thresholds
The ESC provides clear cutoffs for action 7:
- If creatinine rises to >220 μmol/L (2.5 mg/dL): Halve the dose of eplerenone (e.g., to 25 mg on alternate days) and monitor blood chemistry closely
- If creatinine rises to >310 μmol/L (3.5 mg/dL): Stop eplerenone immediately and monitor blood chemistry closely; specific treatment of renal dysfunction may be needed
Drug Interactions Increasing AKI Risk
NSAIDs combined with eplerenone may cause acute kidney failure by direct impact on glomerular filtration, especially in at-risk patients (elderly and/or dehydrated) 8. Patients receiving eplerenone and NSAIDs need to be well-hydrated, and renal function should be checked before treatment initiation 8.
Cyclosporine and tacrolimus may impair renal function and increase risk when combined with eplerenone; this association should be avoided, or if unavoidable, renal function must be closely monitored 8.
Critical Monitoring Algorithm
For Both Medications:
Before initiation: Check baseline renal function and serum electrolytes 7
Early monitoring:
Ongoing surveillance:
High-risk populations requiring intensified monitoring:
Common Pitfalls to Avoid
Do not discontinue these medications for mild or transient reductions in renal function 10. Small to moderate worsening of renal function (defined as ≥20% decrease in eGFR) was not associated with true AKI in heart failure patients on guideline-directed medical therapy 10.
Correct volume or salt depletion prior to administration of Entresto, as volume-depleted patients are at greater risk for both hypotension and renal dysfunction 1.
The "triple whammy" combination (RAAS inhibitor + diuretic + NSAID) substantially increases AKI risk and should be avoided when possible 11. If unavoidable, ensure adequate hydration and close monitoring 8.
Patients with diabetes on these medications have worse safety outcomes and higher 30-day readmission rates, requiring particularly close monitoring 3.